Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1351 - 1375 of 1455 in total
CEP-37440 has been used in trials studying the treatment of Solid Tumors.
Investigational
Experimental
Illicit
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Experimental
Fominoben is an antitussive agent.
Experimental
Withdrawn
Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants . Tianeptine was discovered and...
Investigational
Otenabant has been investigated for the treatment of Obesity.
Investigational
Sapitinib has been used in trials studying the treatment and basic science of Neoplasms, Breast Cancer, Breast Neoplasms, Metastatic Cancer, and Metastatic Breast Cancer, among others.
Investigational
Bizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Experimental
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Acifluorfen is a protoporphyrinogen oxidase inhibitor.
Experimental
Displaying drugs 1351 - 1375 of 1455 in total